<DOC>
	<DOCNO>NCT00675194</DOCNO>
	<brief_summary>The purpose study determine Arm ( capecitabine + irinotecan versus capecitabine + cisplatin ) show high response rate treatment advance gastric-oesophagal cancer Furthermore , comparison progression-free survival , 1-year survival , Quality Life safety</brief_summary>
	<brief_title>Efficacy Irinotecan Capecitabine Versus ( v ) Cisplatin Capecitabine Patients With Esophago-Gastric Cancer</brief_title>
	<detailed_description>capecitabine + irinotecan versus capecitabine + cisplatin , publish Kang et al . ( ASCO 2006 )</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>gastric gastricoesophagal junction adenocarcinoma unidimensional measurable disease Karnofsky index &gt; /=60 % prior chemo radiotherapy colorectal diseases brain metastasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>cisplatin</keyword>
	<keyword>capecitabine</keyword>
	<keyword>gastric</keyword>
	<keyword>irinotecan</keyword>
	<keyword>metastatic</keyword>
	<keyword>chemotherapy</keyword>
</DOC>